MDB Capital Holdings Reports Third Quarter 2024 Developments
MDB Capital Holdings, LLC (NASDAQ: MDBH), known for its focus on innovative deep technology ventures, has shared its operational update for the third quarter of 2024. The company continues to elevate its capabilities and forge strong ties within the investor community.
Strengthening Operations and Investor Relationships
Christopher Marlett, the CEO and Co-Founder of MDB, emphasizes that the company has made significant strides in enhancing operational efficiency this year. "Our main goal has been to cultivate and evaluate promising deep technology ideas, enabling us to finance and nurture them into market leaders," he stated. Notably, MDB has expanded its services to include self-clearing brokerage and established new partnerships, such as with TCA Venture Group, one of the largest angel investor networks, which further diversifies their investment strategy.
Operational Highlights for Q3 2024
During the third quarter, MDB achieved remarkable milestones, including:
- Successful IPO for Invizyne Technologies: On November 13, Invizyne Technologies commenced trading on NASDAQ under the ticker symbol "IZTC." MDB co-founded the company, which specializes in enzyme-based biomanufacturing systems, and retains a substantial ownership with approximately 48% of the shares.
- Collaboration with Mayo Clinic: MDB formed a partnership with Mayo Clinic to develop innovative anti-senescence therapies, initially investing with a $150,000 fee for patent rights. This initiative is aimed at enhancing research in longevity and age-related diseases.
- Expanded Research Capabilities: The team has grown to include thirteen trained analysts, which has allowed MDB to screen over 8,700 companies, identifying 217 with the potential for market leadership, laying the foundation for future innovations.
- Increased Engagements Through PatentVest: MDB has broadened its service offerings, working with eight clients to build intellectual property strategies aimed at empowering technology companies.
- Enhanced Investor Relations: Since the end of last year, MDB has expanded its shareholder base by 15%, onboarding over 450 brokerage accounts and boosting assets under management significantly.
Financial Overview and Upcoming Webinar
MDB has filed its Form 10-Q with the SEC, detailing financial results from all operations up to the quarter end. The upcoming investor call, set for later today, will be led by CEO Marlett and will discuss recent developments, strategies, and financial insights.
About MDB Capital Holdings
Founded in 1997, MDB Capital is dedicated to transforming innovative technologies into valuable public entities through novel public venture capital approaches. Its framework focuses on pre-revenue, early-stage deep technology firms and encompasses both IPO and post-IPO offerings.
Contact Information
For potential investors and media inquiries, reach MDB through:
Investor Relations:
Email: IR@mdb.com
Media Contact:
Email: press@mdb.com
Frequently Asked Questions
What is MDB Capital's core focus?
MDB Capital specializes in launching and financing deep technology companies, helping them transition into successful public markets.
What recent achievements has MDB Capital accomplished in Q3 2024?
The company successfully launched Invizyne Technologies’ IPO and expanded its operations, including a partnership with Mayo Clinic.
How has MDB Capital expanded its investor relationships?
MDB has increased its shareholder base by 15%, establishing over 450 new brokerage accounts and expanding assets under management considerably.
Who leads MDB Capital's third-quarter call?
CEO Christopher Marlett will lead the upcoming discussion, elaborating on recent developments and future strategies.
Where can I find more information about MDB Capital?
Additional information is available on their official website at www.mdb.com.
